The clinical information you need, at your fingertips.

Newly approved use broadens access to a once-daily oral JAK inhibitor for younger patients with challenging disease. . .

Phase 3 TRIUMPH-2 results suggest the triple-agonist delivers substantial weight loss and glycemic improvements over 80 weeks. . .

Sugar-rich foods eaten during broad-spectrum courses predicted a substantial diet-linked decline in gut bacterial diversity. . .

A new ACC nutrition statement challenges federal dietary guidance, naming higher protein targets and full-fat animal foods as not aligned with the evidence. . .

Phase 2 data suggest petrelintide may offer a well-tolerated alternative to incretin-based obesity therapies. . .

The therapy addresses excess thyroid hormone exposure in a rare X-linked genetic disorder. . .

Updated recommendations expand use of dolutegravir/lamivudine and add new two-drug regimen options for selected patients. . .